Background: Turner’s syndrome is a genetic disorder of females with well-described karyotypic abnormalities and phenotypic features. Recombinant human growth hormone (HGH) therapy is one component of a hormonal treatment strategy for these patients and is used to promote sexual maturity and to increase height. Methods: Literature review of hepatic complications following the initiation of growth hormone therapy for patients with Turner’s syndrome, and case report presentation of a 13-year-old female with Turner’s syndrome developing a hepatic adenoma following 3 years of HGH treatment. Results: The association between Turner’s syndrome and HGH treatment-associated hepatic adenoma has not been described previous to this report. In this patient, surgical resection was contraindicated and the patient was successfully treated by hepatic artery embolization. The unique management issues relating to this case, and a possible association between HGH therapy and the development of hepatic adenoma are discussed. Conclusion: This work represents the first documentation of a hepatic adenoma developing in a patient with Turner’s syndrome following HGH treatment, and suggests a novel and causal association between HGH treatment and the development of hepatic adenoma in patients with Turner’s syndrome.

Keywords:
Growth hormone, Turner’s syndrome, Hepatic adenoma
1.
Ross JL, Feuillan P, Kushner H, Roeltgen D, Cutler GBJ: Absence of growth hormone effects on cognitive function in girls with Turner’s syndrome. J Clin Endocrinol Metab 1997;82:1814–1817.
2.
Dacou VC, Karavanaki KK, Petrou V, Georgopoulos N, Maniati CM, Mavrou A: The growth pattern and final height of girls with Turner syndrome with and without human growth hormone treatment. Pediatrics 1998;101:663–668.
3.
Watanabe S, Kobayashi Y: Exogenous hormones and human cancer. Jpn J Clin Oncol 1993;23:1–13.
4.
Edmundson HA, Henderson B, Benton B: Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976;294:470–472.
5.
Carrasco D, Barrachina M, Prieto M, Berenguer J: Clomiphene citrate and liver cell adenoma. N Engl J Med 1984;310:1120–1121.
6.
Coombes GB, Reiser J, Paradinas FJ, Burn I: An androgen-associated hepatic adenoma in a transsexual. Br J Surg 1978;65:869–870.
7.
Fermand JP, Levy Y, Bouscary D, D’Agay MF, Clot P, Frija J, Brouet JC: Danazol-induced hepatocellular adenoma. Am J Med 1990;88:529–530.
8.
Beuers U, Richter WO, Ritter MM, Eiebecke B, Schwandt P: Klinefelter’s syndrome and liver adenoma. J Clin Gastroenterol 1991;13:214–216.
9.
Moller S, Becker U, Gronbaek M, Juul A, Winkler K, Skakkebaek NE: Short-term effect of recombinant human hormone in patients with alcoholic cirrhosis. J Hepatol 1994;21:710–717.
10.
Greer RM, Quirk P, Cleghorn GJ, Sheperd RW: Growth hormone resistance and somatomedins in children with end-stage liver disease awaiting transplantation. J Pediatr Gastroenterol Nutr 1998;27:148–154.
© 2000 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.